Sagimet Biosciences (SGMT) Competitors

Verve Therapeutics (NASDAQ:VERV) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Which has stronger earnings & valuation, VERV or SGMT?

Sagimet Biosciences has lower revenue, but higher earnings than Verve Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verve Therapeutics	$32.33M	30.08	-$198.71M	-$2.11	-5.17
Sagimet Biosciences	$2M	144.30	-$45.57M	-$1.76	-5.35

Do institutionals and insiders believe in VERV or SGMT?

97.1% of Verve Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 19.9% of Verve Therapeutics shares are held by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is VERV or SGMT more profitable?

Sagimet Biosciences has a net margin of 0.00% compared to Verve Therapeutics' net margin of -303.64%. Sagimet Biosciences' return on equity of -35.21% beat Verve Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verve Therapeutics	-303.64%	-35.81%	-27.57%
Sagimet Biosciences	N/A	-35.21%	-34.09%

Do analysts prefer VERV or SGMT?

Verve Therapeutics currently has a consensus price target of $14.57, indicating a potential upside of 33.56%. Sagimet Biosciences has a consensus price target of $26.60, indicating a potential upside of 182.68%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Verve Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verve Therapeutics	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sagimet Biosciences	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, VERV or SGMT?

Verve Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.35, meaning that its share price is 235% more volatile than the S&P 500.

Does the media prefer VERV or SGMT?

In the previous week, Verve Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 3 mentions for Verve Therapeutics and 1 mentions for Sagimet Biosciences. Verve Therapeutics' average media sentiment score of 0.32 beat Sagimet Biosciences' score of 0.00 indicating that Verve Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verve Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sagimet Biosciences beats Verve Therapeutics on 9 of the 16 factors compared between the two stocks.